• Worst Pills, Best Pills



• Health Letter



• Health Links



• Activist Courses



• Take Action!



• Drug Safety



• Healthcare Delivery



• Medical Devices



• Food Safety



• Occupational Health

Publications:

» (6/9/09) Critique of New Antiarrhythmic Drug Dronedarone Published in the New England Journal of Medicine (HRG Publication #1878) » (2/19/09) Letter to FDA About Safety Concerns with Prasugrel Hydrochloride and Removal of Dr. Sanjay Kaul from Cardiovascular and Renal Drugs Advisory Committee Meeting (HRG Publication #1857) » (12/13/07) Testimony on the public health dangers of making lovastatin (MEVACOR) available over-the-counter (HRG Publication #1829) » (4/5/05) Statin-associated rhabdomyolysis (HRG Publication #1733) » (3/14/05) Statement of Sidney Wolfe, M.D. regarding the FDA's decision to leave Crestor on the market (HRG Publication #1730) » (3/10/05) Letter to FDA shows that Crestor has higher rates of rhabdomyolysis compared to other statins (HRG Publication #1729) » (1/14/05) The Serious Public Health Dangers of Prescription-to-OTC Switch of Lovastatin (HRG Publication #1719) » (11/29/04) Letter to FDA urging action on misleading CRESTOR advertising by AstraZeneca (HRG Publication #1712) » (10/29/04) Letter to FDA Renewing Call for Crestor to Be Removed From Market. Rate of Kidney Damage in Crestor Patients Is 75 Times Higher Than in Patients Taking Other Cholesterol Drugs (HRG Publication #1710) » (10/18/04) Dangers of rosuvastatin identified before and after FDA approval (HRG publication #1699) » (9/10/04) Testimony before the FDA's Cardiovascular and Renal Drugs Advisory Committee Hearing on Ximelagatran--September 10, 2004 (HRG Publication #1706) » (8/3/04) Letter to FDA calling for criminal investigation of AstraZeneca because the company illegally delayed submitting reports of serious adverse reactions to cholesterol drug Crestor. (HRG Publication #1703) » (7/7/04) Letter to NIH Director questioning the propriety of the actions of a senior NIH scientist who was a consultant for AstraZeneca. (HRG Publication #1700) » (3/4/04) Petition to the FDA to remove the cholesterol-lowering drug rosuvastatin (CRESTOR) from the market (HRG Publication #1693) » (5/24/01) Testimony before the Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee on a petition to relabel doxazosin (Cardura). (HRG Publication #1575) » (7/13/00) Testimony before the Food and Drug Administration's Endocrinologic/Metabolic and Non-Prescription Advisory Committee on prescription to over-the-counter switch. (HRG Publication #1528) » (2/10/99) Letter and documents sent to the Food and Drug Administration urging them to immediately recall all lots of Abbokinase because of possible contamination with infectious agents. (HRG Publication #1473) » (1/28/99) Statement before the Food and Drug Administration's Cardiovascular and Renal Drugs advisory committee urging that they not approve dofetilide (Tikosyn) to prevent recurrent arrythmias. (HRG Publication #1472) » (12/30/98) Letter to the Food and Drug Administration concerning a study in the New England Journal of Medicine amplifying our concerns about the safety of cilostazol (HRG Publication #1468) » (6/8/98) Statement on the withdrawal of mibefradil/Posicor from the market. (HRG Publication #1441) >> more publications...

more resources

Because Public Citizen does not accept funds from corporations, professional associations or government agencies, we can remain independent and follow the truth wherever it may lead. But that means we depend on the generosity of concerned citizens like you for the resources to fight on behalf of the public interest. If you would like to help us in our fight, click here.